Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
May 24 2023 - 8:15AM
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or
“Quoin”), a clinical stage, specialty pharmaceutical company
focused on rare and orphan diseases, announces that its open label
study evaluating QRX003 as a treatment for Netherton Syndrome has
reached 50% enrollment.
The company’s open label study is investigating
the safety and efficacy of QRX003 topical lotion in Netherton
Syndrome patients who are currently receiving off-label systemic
therapy, primarily biologic therapy, and is being conducted under
an open Investigational New Drug (IND).
Quoin announced it had dosed the first patient
in its clinical trial in March 2023 and has now dosed its fifth
patient out of a total of 10 patients that are expected to
participate in this single-arm study.
Quoin Pharmaceuticals CEO, Dr. Michael Myers,
said, “We are very pleased with the level of interest that our two
clinical trials have generated. Reaching 50% enrollment for this,
our open label study, is a very significant milestone and an
important step forward for Quoin as we pursue the development of a
safe and effective treatment for this devastating disease. We
anticipate reporting top-line data from this study in the second
half of 2023.”
In addition to its open label study, Quoin is
conducting a double blinded, vehicle controlled trial assessing two
different doses of QRX003 topical lotion versus a vehicle lotion in
Netherton Syndrome patients. Both studies are actively recruiting
and dosing patients. If proven to be safe and effective, long term
daily application of QRX003 could lead to the development of a more
normally functioning skin barrier and a significant improvement in
the quality of life of Netherton Syndrome patients.
For more information about Quoin’s clinical
trials in Netherton Syndrome, please visit:
https://www.nethertonsyndromeclinicaltrials.com/
About Quoin Pharmaceuticals
Ltd.Quoin Pharmaceuticals Ltd. is a clinical stage
specialty pharmaceutical company focused on developing and
commercializing therapeutic products that treat rare and orphan
diseases. We are committed to addressing unmet medical needs for
patients, their families, communities and care teams. Quoin’s
innovative pipeline comprises four products in development that
collectively have the potential to target a broad number of rare
and orphan indications, including Netherton Syndrome, Peeling Skin
Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis
Bullosa and others. For more information, visit:
www.quoinpharma.com or LinkedIn for updates.
About Netherton
SyndromeNetherton Syndrome is a rare and sometimes fatal
skin disease for which there is no approved treatment, and no cure.
It is caused by a mutation of the SPINK5 gene which leads to
uncontrolled skin shedding, resulting in a highly porous and
ineffective skin barrier. Symptoms are present at birth and include
red, scaly skin. Other symptoms include outbreaks of red, circular
scaly rashes, thin, fragile hair (bamboo hair), and immune
reactions such as hay fever, asthma, severe pruritus (itchy skin),
and eczema. Dehydration and infection are common and can be serious
or fatal. Babies tend to grow slowly and have poor weight gain.
Netherton Syndrome is inherited in an autosomal recessive
pattern.
Cautionary Note Regarding Forward
Looking StatementsThe Company cautions that statements in
this press release that are not a description of historical facts
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words referencing future
events or circumstances such as "expect," "intend," "plan,"
"anticipate," "believe," and "will," among others. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" included
in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2022 that the Company filed with the SEC. One should
not place undue reliance on these forward-looking statements, which
speak only as of the date on which they were made. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. The Company undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as may be required by law.
For further information,
contact:Investor RelationsPCG AdvisoryStephanie
Princesprince@pcgadvisory.com(646) 863-6341
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Apr 2023 to Apr 2024